Travere Therapeutics, Inc. (TVTX) Form 10-Q — Aug 4, 2026
Travere Therapeutics reported Q2 2026 total revenue of $169.6 million, up roughly 48% year over year, driven by FILSPARI net sales of $141.1 million (vs. $71.9 million a year ago) plus a $5.0 million Chugai regulatory milestone. The company posted its first positive quarterly operating income of $4.0 million. GAAP net loss nonetheless widened to $34.8 million, or $(0.37) per share, versus $(12.8) million, or $(0.14), in Q2 2025, entirely due to a one-time $40.0 million inducement expense from the May 2026 partial repurchase of its 2.25% convertible notes due 2029.
Key figures
- Revenue
- 169584000
- Total Debt
- 602781000
- Revenue Yoy
- +48% YoY (Q2 total revenue $169.6M vs $114.4M)
- Cash Position
- 117735000
- Shares Outstanding
- 94261082
- Sga q2
- 96112000
- Total assets
- 799360000
- Filspari h1 sales
- 246230000
- Filspari q2 sales
- 141078000
- Notes 2032 coupon
- 0.50%
- Chugai milestone q2
- 5000000
- Operating income q2
- 3954000
- Stockholders equity
- 24522000
- Anti dilutive shares
- 24493329
- Notes 2032 principal
- 525000000
- Inducement expense q2
- 40008000
- Filspari q2 prior year
- 71887000
- Total cash and securities
- 489177000
- Notes 2032 conversion price
- approximately $64.90 per share
- Everest potential milestones
- up to approximately $1.03 billion
- Everest upfront paid july 2026
- 112500000
- Notes 2029 remaining principal
- 94900000
- Notes 2029 repurchase cash paid
- 350900000
- Notes 2029 repurchased principal
- 221400000
Price after filing
Close on the filing date to close N calendar days later (from $57.28). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.